Omeros (NASDAQ:OMER) Upgraded by RODMAN&RENSHAW to Strong-Buy Rating

RODMAN&RENSHAW upgraded shares of Omeros (NASDAQ:OMER) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

OMER has been the topic of several other reports. Rodman & Renshaw started coverage on Omeros in a report on Thursday. They set a “buy” rating and a $9.00 target price on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a report on Thursday. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Thursday. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Omeros presently has an average rating of “Hold” and an average price target of $9.00.

Omeros Trading Up 2.0 %

Shares of Omeros stock traded up $0.14 during trading hours on Thursday, reaching $7.09. The stock had a trading volume of 1,323,976 shares, compared to its average volume of 462,819. The firm has a 50 day simple moving average of $4.08 and a two-hundred day simple moving average of $4.07. The firm has a market capitalization of $410.84 million, a price-to-earnings ratio of -2.89 and a beta of 1.47. Omeros has a 1 year low of $1.38 and a 1 year high of $7.51.

Institutional Investors Weigh In On Omeros

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its stake in Omeros by 75.5% during the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 12,951 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Omeros during the 1st quarter valued at approximately $85,000. Comerica Bank grew its position in shares of Omeros by 20.0% in the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 5,000 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Omeros by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after acquiring an additional 81,348 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after acquiring an additional 31,081 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.